Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Department of Error
The Lancet ( IF 98.4 ) Pub Date : 2024-12-19 , DOI: 10.1016/s0140-6736(24)02716-8
The Lancet ( IF 98.4 ) Pub Date : 2024-12-19 , DOI: 10.1016/s0140-6736(24)02716-8
Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 2024; 404: 1227–39—Appendix 1 of this Article has been corrected as of December 19, 2024.
更新日期：2024-12-20
京公网安备 11010802027423号